| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Mar 8, 2022Data supports clinical investigation of NVL-520 and NVL-655 across various ROS1 or ALK fusion partners, resistance mutations, and tumor types
Nuvalent, Inc., (Nasdaq: NUVL) a biotechnology company creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced multiple preclinical data presentations...
-
Mar 2, 2022
Nuvalent, Inc. (Nasdaq: NUVL), a biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that James Porter,...
-
Feb 3, 2022Industry-leading genomics expertise supports Nuvalent's advancement as a clinical-stage precision oncology company
Nuvalent, Inc. (Nasdaq: NUVL), a biotechnology company creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the appointment of Emily Drabant...
-
Jan 7, 2022ARROS-1 trial enrolling patients with advanced ROS1-positive NSCLC and other solid tumors
Nuvalent, Inc. (Nasdaq: NUVL), a biotechnology company creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that the first patient has been dosed...
-
Jan 4, 2022
Nuvalent, Inc. (Nasdaq: NUVL), a biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that James Porter,...
The information in Nuvalent’s press releases is accurate only as of the date of issuance. Nuvalent assumes no duty to update or revise the information contained in the press releases after their original release date.
